3-[3,4-Bis(phenylmethoxy)phenyl]prop-2-en-1-ol | 87030-14-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醇
• 英文名称: 3-[3,4-Bis(phenylmethoxy)phenyl]prop-2-en-1-ol
• CAS: 87030-14-6
• 化学式: C₂₃H₂₂O₃
• 分子量: 346.426
• InChiKey: MCVHFAQCEVMALC-UHFFFAOYSA-N

物化性质

• 沸点：
  546.1±45.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[3,4-Bis(phenylmethoxy)phenyl]prop-2-en-1-ol 在 potassium osmate(VI) dihydrate 、 甲基磺酰胺 、 potassium carbonate 、 氢化奎尼定 1,4-(2,3-二氮杂萘)二醚 、 potassium hexacyanoferrate(III) 作用下， 以 水 、 叔丁醇 为溶剂， 以73%的产率得到(1R,2R)-1-(3,4-bis(benzyloxy)phenyl)propane-1,2,3-triol
  参考文献：
  名称：

  General synthesis of epi-series catechins and their 3-gallates: reverse polarity strategy

  摘要：

  基于反极性策略，开发了一条合成表儿茶素类化合物的通用合成路线。通过芳香族亲核取代反应、亚磺酰基-金属交换及环化反应，实现了多种表儿茶素及其3-没食子酸酯的立体控制合成。

  DOI：

  10.1039/c003464a
• 作为产物：
  描述：

  3-{3,4-bis(benzyloxy)phenyl}propenoic acid ethyl ester 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 7.5h， 以87%的产率得到3-[3,4-Bis(phenylmethoxy)phenyl]prop-2-en-1-ol
  参考文献：
  名称：

  General synthesis of epi-series catechins and their 3-gallates: reverse polarity strategy

  摘要：

  基于反极性策略，开发了一条合成表儿茶素类化合物的通用合成路线。通过芳香族亲核取代反应、亚磺酰基-金属交换及环化反应，实现了多种表儿茶素及其3-没食子酸酯的立体控制合成。

  DOI：

  10.1039/c003464a

文献信息

• (-)-Epigallocatechin Gallate Derivatives For Inhibiting Proteasome
  申请人：Chan Tak-Hang

  公开号：US20080176931A1

  公开（公告）日：2008-07-24

  (−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R 11 , R 12 , R 13 , R 21 , R 22 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of —H, and C 1 to C 10 acyloxyl group; and R 5 is selected from the group consisting of —H, C 1 -C 10 -alkyl, C 2 -C 10 -alkenyl, C 2 -C 10 -alkynyl, C 3 -C 7 -cycloalkyl, phenyl, benzyl and C 3 -C 7 -cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R 11 , R 12 , R 13 , R 21 , R 22 , R 2 , R 3 and R 4 is —H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth.

  (-)-EGCG是最丰富的儿茶素之一，被发现具有化学预防和抗癌作用。然而，(-)-EGCG至少存在一个限制：其生物利用度较低。本发明提供了一般化学式如下的化合物，其中R11、R12、R13、R21、R22、R2、R3和R4各自独立地选择自-H和C1到C10酰氧基的群组成；而R5选择自-H、C1-C10烷基、C2-C10烯基、C2-C10炔基、C3-C7环烷基、苯基、苄基和C3-C7环烯基，而最后提到的7个基团中的每一个都可以用任意组合的1到6个卤素原子取代；其中至少有一个是R11、R12、R13、R21、R22、R2、R3和R4中的-H，这些化合物比其非保护的对应物更有效，可用作蛋白酶体抑制剂来减少肿瘤细胞生长。
• Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues
  申请人：Romanczyk, JR. Leo J.

  公开号：US20100048920A1

  公开（公告）日：2010-02-25

  Processes for preparing racemic mixtures of 5,7,3′,4′-tetra-O-benzyl-(±)-catechin and (±)-epicatechin involves (i) condensing 2-hydroxy-4,6-bis(benzyloxy)-acetophenone and 3,4-bis(benzyloxy)benzaldehyde, cyclizing the resulting compound, oxidizing the resulting compound; (ii) dihydroxylating (E)-3-(3′,4′-bis(benzyloxy)phenyl)prop-2-ene-1-ol and reducing the 1,2-diol; or (iii) coupling 3,5-bis(benzyloxy)phenol with (E)-3,5-bis(benzyloxy)-2-(3′,4′-bis(benzyloxy)phenyl)allyl)phenol and cyclizing the resulting chalcone. A process for preparing the benzylated epimers of catechin and epicatechin involves seven steps. 3,4-Bis(benzyloxy)benzaldehyde is coupled with 2-hydroxy-4,6-benzyloxy-acetophenone to form a chalcone. The chalcone is selectively reduced to an alkene. The phenolic group of the alkene is protected. The protected alkene is asymetrically dihydroxylated. The resulting compound is deprotected, cyclized, and finally hydrolyzed. Epimers resulting from these processes are chemically resolved or separated by chiral high pressure liquid chromatography. Also disclosed is a method for preparing enantiomerically pure 5,7,3′,4′-tetra-O-benzyl-(+)-catechin from a racemic mixture using dibenzoyl-L-tartaric acid monomethyl ester. Further, disclosed is an improved process for preparing dibenzoyl-L-tartaric acid monomethyl ester.

  制备5,7,3′,4′-四-O-苄基-(±)-儿茶素和(±)-表儿茶素的外消旋混合物的过程包括：(i)缩合2-羟基-4,6-双(苄氧基)-乙酮和3,4-双(苄氧基)苯甲醛，环化生成化合物，氧化化合物；(ii)双羟基化(E)-3-(3′,4′-双(苄氧基)苯基)丙-2-烯-1-醇，还原1,2-二醇；或(iii)将3,5-双(苄氧基)苯酚与(E)-3,5-双(苄氧基)-2-(3′,4′-双(苄氧基)苯基)丙烯基)苯酚偶联，生成的查尔酮环化。制备儿茶素和表儿茶素的苄基异构体的过程包括七个步骤。3,4-双(苄氧基)苯甲醛与2-羟基-4,6-双(苄氧基)-乙酮偶联形成查尔酮。查尔酮被选择性还原为烯烃。烯烃的酚基被保护。保护的烯烃被不对称地二羟基化。生成的化合物被去保护，环化，最后水解。这些过程生成的异构体通过手性高压液相色谱进行化学分离。还公开了一种使用二苯乙酰-L-酒石酸单甲酯制备对映纯5,7,3′,4′-四-O-苄基-(+)-儿茶素的方法。此外，还公开了一种改进的制备二苯乙酰-L-酒石酸单甲酯的方法。
• (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome
  申请人：CHAN Tak-Hang

  公开号：US20120232135A1

  公开（公告）日：2012-09-13

  A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:

  一种减少肿瘤细胞生长的方法，包括给予一种具有以下化学式的化合物的有效剂量：
• (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME
  申请人：The Hong Kong Polytechnic University

  公开号：US20160068503A1

  公开（公告）日：2016-03-10

  A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:

  一种减少肿瘤细胞生长的方法，该方法包括给予一种具有以下公式的化合物的有效量：
• Substituted pyrrolidine cardiovascular system regulators and antihypertensives, their preparation and use
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0071399A2

  公开（公告）日：1983-02-09

  Compounds of the formula: and the pharmaceutically acceptable acid addition salts thereof, wherein: each X is indeoendently selected from -F, -R1, -OR. -S(O)dR', -CONHR, -NHR, -CH2OR, -CN, -NHCONHR, -NHCSNHR, -NHCOR', -SO2NHR, -NHSO2R1, and -NHCO2R wherein R is either hydrogen or lower alkyl wherein lower alkyl is defined as a straight or branched hydrocarbon chain of 1-4 carbon atoms, R' is lower alkyl wherein alkyl is as defined above and d is 0, 1, or 2, or two Xs taken together are -OCH2O-; each Y is independently selected from the same group as set forth for X; B is hydrogen or hydroxyl; a is 0, 1, or 2; b is 0, 1, or 2; c is 0, 1, 2 or 3; are useful as regulators of the cardiovascular system and are also bronchodilators.

  式化合物 及其药学上可接受的酸加成盐，其中 每个 X 不可重复地选自 -F、-R1、-OR.-S(O)dR'、-CONHR、-NHR、-CH2OR、-CN、-NHCONHR、-NHCSNHR、-NHCOR'、-SO2NHR、-NHSO2R1 和 -NHCO2R，其中 R 是氢或低级烷基，其中低级烷基定义为 1-4 个碳原子的直链或支链烃链，R'是低级烷基，其中烷基定义如上，d 是 0、1 或 2，或两个 X 合在一起是 -OCH2O-； 每个 Y 独立地选自与 X 相同的组； B 是氢或羟基； a 是 0、1 或 2 b 是 0、1 或 2 c 是 0、1、2 或 3；可作为心血管系统的调节剂，也是支气管扩张剂。